ClinicalTrials.gg
CompletedNCT01817465Updated Jan 27, 2015

A Study to Demonstrate the Efficacy and Safety of Motilitone®

A Phase 4 interventional study of Motilitone ® and Pantoline® in Functional Dyspepsia, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-01-27.

Sponsored by Dong-A ST Co., Ltd. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
389
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies in Dyspepsia with a site in Korea, Republic of — 3 open to participants now, 4 under way, none of them phase 3. Dyspepsia · Korea, Republic of.

Enrollment
2nd of 26
389 · median 100
Started
2012
the only one that year
Phase 4
8 of 28
2 open now
Registered
3rd of 28
by date
Lead sponsor
3 of 28
Dong-A ST Co., Ltd.

Among the 28 studies in Dyspepsia with a site in Korea, Republic of, this one is the 2nd largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2012, is one of 8 in phase 4, and was the 3rd registered.

Dyspepsia

372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

3 of the 28 studies in Dyspepsia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Dyspepsia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a phase IV , comparative study to evaluate the efficacy and safety of Motiltone® in treatment of the patients with functional dyspepsia. The study is conducted with following methods: multi-centers, double blind, randomization, parallel. The subjects will receive Motilitone® or/and Pantoline®.

03

Conditions studied

  • Functional Dyspepsia

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Roman III criteria
  • One or more conditions are applied: epigastralgia, burning feelings in the solar plexus early satiety, uncomfortable fullness
  • No organic lesion

Exclusion criteria

Exclusion Criteria:

  • has been administered or was administered within a month
  • had a surgery that might affect gastrointestinal motility
  • Tegaserod
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
389 participants (actual)

Study arms

  • Experimental
    Motilione®

    30 mg is administered with a tablet of placebo (Pantoline®)

    Drug: Motilitone ®

  • Active comparator
    Pantoline®

    40mg is administered with a tablet of Motilitone®

    Drug: Pantoline®

  • Active comparator
    Motilitone® and Pantoline®

    Both drugs are administered at once

    Drug: Motilitone® and Pantoline®

Interventions

06

What researchers measure

Primary outcomes

  1. Subject global assessment by using 5-Likert scale and Binary outcome methods

    5-Likert scale: 0: worse 1. similar 2. improved in some degree 3. considerably improved 4. completely cured Binary outcome: yes/no

    Time frame: 6 weeks

Secondary outcomes

  1. Number of dyspepsia(indigestion) symptoms occurred (Counted daily)

    Time frame: 6 weeks

  2. Assessment of NDI-K Quality of Life

    Time frame: 6 weeks

  3. Soreness of digestive symptoms (dyspepsia) evaluated its intensity on a scale of 1 to 5

    Time frame: 6 weeks

07

Study locations

1 site
  • Ajou University Medical Center
    Suwon, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2013
First posted
Mar 25, 2013
Start
Aug 2012
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Last update
Jan 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01817465
Responsible party
Sponsor
First posted
Mar 25, 2013
Start date
Aug 2012
Primary completion
Mar 2014
Completion
Mar 2014
Last update
Jan 27, 2015

Study contacts

Myung Kyu Choi, M.D., Ph.D.
principal investigator · The Catholic University of Korea
Kyu Chan Huh, M.D., Ph.D.
principal investigator · Konyang University Hospital
Sung Kook Kim, M.D., Ph.D.
principal investigator · Kyungpook National University Hospital
Kyung Sik Park, M.D., Ph.D.
principal investigator · Keimyung University Dongsan Medical Center
Joong Gu Gweon, M.D.,Ph.D.
principal investigator · Daegu Catholic University Medical Center
Geun Am Song, M.D., Ph.D.
principal investigator · Busan National University Hospital
Soo Jin Hong, M.D., Ph.D.
principal investigator · Soonchunhyang University Hospital
Na Young Kim, M.D., Ph.D.
principal investigator · Seoul National University Bundang Hospital
Jung Il Son, M.D., Ph.D.
principal investigator · Kangbuk Samsung Hospital
Poong Yul Lee, M.D., Ph.D.
principal investigator · Samsung Medical Center
Joon Sung Lee, M.D., Ph.D.
principal investigator · Soonchunhyang University Hospital
Hoon Yong Jung, M.D., Ph.D.
principal investigator · Asan Medical Center
Hyo Jin Park, M.D., Ph.D.
principal investigator · Gangnam Severance Hospital
Yong Chan Lee, M.D., Ph.D.
principal investigator · Severance Hospital
Suk Chae Choi, M.D., Ph.D.
principal investigator · Wonkwang Medical Center
Hye Kyung Jung, M.D., Ph.D.
principal investigator · Iwha Womans Unversity Mokdong Hospital
Sam Ryong Ji, M.D., Ph.D.
principal investigator · Inje University
Jong Sun Ryu, M.D., Ph.D.
principal investigator · Chonnam National University Hospital
Oh Young Lee, M.D., Ph.D.
principal investigator · Hanyang University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DA-9701

Start the discussion